Hao X, Bishop A E, Wallace M, Wang H, Willcocks T C, Maclouf J, Polak J M, Knight S, Talbot I C
Academic Department of Pathology, St Mark's Hospital, Harrow, U.K.
J Pathol. 1999 Feb;187(3):295-301. doi: 10.1002/(SICI)1096-9896(199902)187:3<295::AID-PATH254>3.0.CO;2-Y.
Regular administration of non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the incidence of colorectal cancer by targeting cyclo-oxygenase-2 (Cox-2), a key enzyme in arachidonic acid metabolism. To evaluate the role of Cox-2 in sporadic colorectal cancer development, Cox-2 expression was investigated by immunohistochemistry in 85 adenomas, 53 carcinomas, 34 hyperplastic lesions and 104 samples of histologically normal mucosa adjacent to adenoma or carcinoma. In addition, Cox-2 mRNA expression was assessed by reverse transcription-polymerase chain reaction (RT-PCR) in six adenomas and 14 carcinomas with paired grossly normal mucosa. Immunohistochemistry for the proliferation-associated antigen Ki-67 and in situ end labelling for demonstrating apoptotic bodies were also used to analyse the associations between Cox-2 expression and proliferation and apoptosis. Cox-2 protein expression was increased in 76/85 (89.4 per cent) adenomas and 44/53 (83.0 per cent) carcinomas compared with normal mucosa. Cox-2 protein expression was unrelated either to the degree of dysplasia or to the size of the adenomas (p > 0.50, p > 0.10, respectively) or to differentiation, Dukes stage or lymph node metastasis of carcinomas (all p > 0.50). Interestingly, 20/34 (58.8 per cent) hyperplastic lesions adjacent to adenomas or carcinomas displayed expression higher than in normal mucosa (18.3 per cent) (p < 0.0001) but lower than in adenomas or carcinomas (p < 10(-5), p < 0.001, respectively). There were no correlations between Cox-2 protein expression and proliferative or apoptotic index in either adenomas or carcinomas (all p > 0.25). Cox-2 mRNA expression was significantly increased in adenomas and carcinomas compared with normal mucosa (p < 0.005, p < 0.001, respectively). There were no differences between adenomas and carcinomas in either protein or mRNA levels (p > 0.25, p > 0.90, respectively). These data indicate that enhanced expression of Cox-2 occurs early during colorectal carcinogenesis and may contribute to tumour formation.
定期服用非甾体抗炎药(NSAIDs)可能通过作用于环氧化酶-2(Cox-2)来降低结直肠癌的发病率,Cox-2是花生四烯酸代谢中的关键酶。为了评估Cox-2在散发性结直肠癌发生中的作用,采用免疫组织化学方法对85例腺瘤、53例癌、34例增生性病变以及104例与腺瘤或癌相邻的组织学正常黏膜样本进行了Cox-2表达研究。此外,采用逆转录聚合酶链反应(RT-PCR)对6例腺瘤和14例癌及其配对的大体正常黏膜进行了Cox-2 mRNA表达评估。还使用了增殖相关抗原Ki-67的免疫组织化学和用于显示凋亡小体的原位末端标记来分析Cox-2表达与增殖和凋亡之间的关联。与正常黏膜相比,76/85(89.4%)的腺瘤和44/53(83.0%)的癌中Cox-2蛋白表达增加。Cox-2蛋白表达与腺瘤的发育异常程度或大小无关(分别为p>0.50,p>0.10),也与癌的分化、Dukes分期或淋巴结转移无关(所有p>0.50)。有趣的是,与腺瘤或癌相邻的20/34(58.8%)增生性病变的表达高于正常黏膜(18.3%)(p<0.0001),但低于腺瘤或癌(分别为p<10⁻⁵,p<0.001)。在腺瘤或癌中,Cox-2蛋白表达与增殖指数或凋亡指数均无相关性(所有p>0.25)。与正常黏膜相比,腺瘤和癌中的Cox-2 mRNA表达均显著增加(分别为p<0.005,p<0.001)。腺瘤和癌在蛋白或mRNA水平上均无差异(分别为p>0.25,p>0.90)。这些数据表明,Cox-2表达增强在结直肠癌发生早期就已出现,可能有助于肿瘤形成。